Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Everolimus and Ribociclib in HER2-negative Metastatic Breast Cancer with Persistent HER2-negative CTCs
2013-001269-18Phase 2Completed
- Sponsor
- University Hospital Ulm
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of everolimus and ribociclib in breast cancer, sponsored by University Hospital Ulm. Primary endpoints: Overall response rate (ORR), Disease control rate (DCR) and 1 more. Started Aug 2013; status: completed.
02
Drugs
everolimusribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-001269-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001269-18.